CompletedPhase 1

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Lead sponsor

AstraZeneca

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•BMI 19-40•HbA1c 7-10%

Primary endpoint

•To detect the mean difference in half gastric emptying time for a solid meal

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00517283

Org study IDH8O-EW-GWAM

Timeline

Milestones

Study first posted2007-08-16estimated

Last update posted2015-02-23estimated

Study start2005-01 (month precision)

Primary completion2005-06actual (month precision)

Study completion2005-06actual (month precision)

Assets

Investigational agents

Exenatide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age25 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subjects with at least 1 year history of type 2 diabetes mellitus.

•Subjects controlled by oral antidiabetic agents or diet and exercise demonstrated by a screening HbA1c ≥7.0% and ≤10.0%.

•Between the body mass index (BMI) of 19 kg/m2 and 40 kg/m2, inclusive.

Exclusion criteria

•Within 4 months of the initial dose of study drug, have received a drug that has not received regulatory approval for any indication.

•Persons who have previously completed or withdrawn from this study or any other study investigating exenatide.

•Subjects who are using drugs that significantly affect gastrointestinal motility (including acarbose, metoclopramide, and macrolide antibiotics).

•Subjects who intend to start new concomitant medication during the study, including over-the counter medication, apart from occasional intake of paracetamol or vitamin/mineral supplements. Anti-emetic medication may be permitted at the investigator's discretion, except those that affect gastrointestinal motility.

•Subjects who have used insulin for more than 4 weeks within 3 months prior to screening.

•Blood donation of more than 500 mL in the last 3 months of screening or any blood donation within the last month.

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

1 endpoint

Primary/protocol endpoint

To detect the mean difference in half gastric emptying time for a solid meal between any treatment and placebo

Time frame:up to 12 hours post meal consumption

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.